BMO Capital Maintains Outperform on Biogen, Lowers Price Target to $295
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) but lowered the price target from $314 to $295.

November 09, 2023 | 7:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's price target has been lowered from $314 to $295 by BMO Capital, although the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100